We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Re Casanova, hope this helps,
Jean-Laurent Casanova, a geneticist at the Rockefeller University in New York City. He co-leads a consortium called the COVID Human Genetic Effort, which in September 2020 reported7 spotting mutations in people with severe COVID-19 that disable genes involved in a potent antiviral response, called type 1 interferon immunity. (One of the genes in which they found mutations, IFNAR2, which codes for a subunit of an interferon receptor, has also been flagged by multiple GWAS.) The mutations identified by Casanova’s team were rare, but in a follow-up study8, the researchers found that 10% of people with life-threatening COVID-19 produced antibodies that inactivate type 1 interferons — mimicking the effects of the gene mutations. Casanova says his team looked for them only after they identified the genetic mutations, underscoring the power of his approach to point to new lines of research. “Essentially what we’ve cracked is a mechanism of critical COVID-19 pneumonia,” he says.
Thanks for the roundup Wigster77 and Doc83, very much appreciated. I am encouraged to hear they hope to land on one or more platform trial(s). Likely to be the most productive way forward and certainly best for keeping down cash-burn.
This is clearly why Poly are still onboard and it’s interesting that despite the usual suspects comments about Polys intentions being suspect.
The BOD have found the exact opposite.
Graham - it is all coming back to me now, including the little one liners.
SS (who I personally found quite impressive) said “clearly there is more than just hope going on here” or words very similar.
After the BOD comments today and the emphasis they placed on broad spectrum and ability to treat multiple viruses. I think it may be the new Strive platform trial. That may just be a shot in the dark, but interesting all the same.
Many thanks for the summary both. You've provided some clarity amongst all the doubts.
Thanks Graham....
Looks like they are confident a Platform trial is going ahead....
Maybe that is why Poly keep adding......
GLA!
Thank you both (doc and wigster) for the detailed and impartial synopsis. Makes for a good read and cements a positive view.
Thank you Wig and Doc, I really appreciate the effort. Very detailed. Let's wait and be positive.
Thank you very much doc and wigster .
As a relatively new investor I find your review extremely helpful.
Brilliant Chaps....I finally feel I know where we are...THANK YOU BOTH!!
A great post of events today and much appreciated for the Synairgen shareholders. many thanks Doc83, Wigster
Key point for me was his strong assertion that they’d be likely treating patients this winter. Which suggests a Trial is well in hand
Maybe the biggest one of them all missing from the Q&A happy to add on.
Q do you see Synairgen treating patients in a hospital either in the UK or USA this winter?
A RM I would envisage yes, I’m happy to say I strongly envisage we will be. Subject to ongoing discussions.
A master piece, feel a bit more confident now Thanks.
Many thanks wigster and doc83, that’s massively helpful
BTW...the scientists on Twitter, I find a few them by keeping an eye on Bloom Labs - various scientists are catalog-ing the next lot of variants. The thing is moving and shifting. Its not so much 'over' as finding new places from which to begin. So Covid is now creating a new post-Omicron family, as I understand it. And will be re-launching itself from that place. This is a long play.
Very well done chaps. Bravo. (and thank you)
Thank you very much Wigster and Doc83. You have done really well. That is first class work.
I hope Synairgen themselves have a good look at what you have produced. It is so much more informative and helpful than the colder style of the RNS or the Proactive interviews. If I'm right in thinking that many of the questions came from this board -then we have done really well as a team in terms of drawing out some very interesting information.
Synairgen remains a buy. Especially at this price point. Or anything under 40p IMO. But as Ghia noted, be patient.
Thanks both for compiling this.
Very much appreciated.
SNG is not dead yet. It is sleeping and one day in the future it will wake up and surprise us all.
Headache.. no wonder after all that.
Yeah it was 4am start for me. I was back in Lancaster at 1500hrs in a bit of a daze
ATB
Many thanks for your comprehensive report Wigster, really appreciate the effort that you and Doc83 have put in to this and also for all other updates on todays meeting.
Wigster77 and Doc83............Thank you so much for such a detailed report.
Thanks HPHQ. It was some effort and a very early start. But good for everyone to hopefully glean something from the AGM. Banging headache now… I promise nothing to do with the “few” pints of Doom Bar post AGM and debrief… ;)
Yes superb report thanks .
We are still in the game - Activ 2 , a new platform trial . Long Covid data . COPD/Asthma
SNG001 is still there as one of the best candidates as a non invasive , variant agnostic , all purpose antiviral treatment for respiratory illness .
Huge amount of data gathered from various trials .
Professional team of experts pushing the program .
Not sure its totally 'bottom drawer' material .
May be a long road , but could be some nice surprises along the way .
Just waiting for its day in the sun .
Very well done you two!
I can confirm that they pretty much nailed it.
Bravo